Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.

Journal Article (Journal Article)

The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.

Full Text

Duke Authors

Cited Authors

  • Meriggioli, MN; Ciafaloni, E; Al-Hayk, KA; Rowin, J; Tucker-Lipscomb, B; Massey, JM; Sanders, DB

Published Date

  • November 25, 2003

Published In

Volume / Issue

  • 61 / 10

Start / End Page

  • 1438 - 1440

PubMed ID

  • 14638974

Electronic International Standard Serial Number (EISSN)

  • 1526-632X

Digital Object Identifier (DOI)

  • 10.1212/01.wnl.0000094122.88929.0b


  • eng

Conference Location

  • United States